TTrialPathMatch Me to Trials
← Back to trials
RecruitingHepatorenal SyndromeAcute Kidney Injury

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

Eligible age

18+ yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI

Sponsor: River 2 Renal Corp.

You may qualify if…

  • ✓ 1. Patient is able to communicate well with the Investigator, understands and is willing to comply with all requirements of the study, and understands and signs the written informed consent form (ICF).
  • ✓ 2. At least 18 years of age.
  • ✓ 3. Cirrhosis and ascites.
  • ✓ 4. AKI stage 2 or 3. AKI defined by any of the following: 1) increase in SCr (SCr) ≥ 0.3 mg/dl (or ≥ 26.5 micromolar/L) within 48 h, or 2) increase ≥ 50% in baseline SCr, which is known or presumed to have occurred within the prior seven days.
  • ✓ 5. QLY SCr ≥ to 1.5 mg/dl.
  • ✓ 6. No sustained improvement in renal function (less than 20% decrease in SCr and SCr =\> 1.5 mg/dL) after 48 h of diuretic withdrawal and the beginning of plasma volume expansion with albumin.
  • ✓ 7. Female patients as well as female partners of male patients must be willing to avoid pregnancy for the duration of the study (\>90 days).

You may not qualify if…

  • ✕ 1. Significant co-morbidities that in the opinion of the Investigator would preclude study participation.
  • ✕ 2. QLY SCr level \> 5 mg/dL.
  • ✕ 3. AKI stage 1.
  • ✕ 4. ACLF stage 3.
  • ✕ 5. Model for End-Stage Liver Disease (MELD) score \>35.
  • ✕ 6. At least one event of large volume paracentesis (LVP) \> 4 Liters in the last 4 days before enrollment.
  • ✕ 7. Current or recent (within 4 weeks) treatment with nephrotoxic drugs (e.g., aminoglycosides, amphotericin, cyclosporine, NSAIDS (e.g., ibuprofen, naproxen, celecoxib), significant exposure to radiographic contrast agents (large doses or multiple injections of iodinated contrast media).
  • ✕ 8. Shock (hypovolemic-, cardiogenic-, or vasodilatory/distributive shock) with mean arterial blood pressure (MAP) ≤70 mmHg or systolic blood pressure ≤90 mmHg along with hypoperfusion.

Where it's recruiting

California

San Francisco

Georgia

Atlanta

Minnesota

Rochester

Pennsylvania

Philadelphia

Tennessee

Nashville

Texas

Fort Worth

Source: ClinicalTrials.gov · NCT05875948 · last updated 2023-10-03